GlassScriptPhysician profile
Jeffrey Craig
NPI 1578528238
$1,135.89
in general payments reported to CMS, 2019-2025
14 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2021: $167 · 2022: $186 · 2023: $146 · 2024: $171 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $279.41 | 2022-2024 | Mitraclip |
| Edwards Lifesciences Corporation | $162.86 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Axsome Therapeutics, INC. | $148.46 | 2025 | Auvelity |
| Lilly USA, LLC | $145.23 | 2019-2025 | Zepbound, Mounjaro |
| Biohaven Pharmaceuticals, INC. | $109.76 | 2021 | |
| Medtronic Vascular, INC. | $72.71 | 2019 | |
| Amgen INC. | $59.64 | 2023-2025 | Repatha, Otezla, Repatha |
| Arthrex, INC. | $45.00 | 2019 | |
| Nevro Corp. | $21.00 | 2019 | |
| Eisai INC. | $18.91 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.84 | 2021 | |
| Esperion Therapeutics, INC. | $18.81 | 2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $17.67 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $17.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Craig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.